Association of the PPARγ gene polymorphism Pro12Ala with delayed onset of multiple sclerosis

Neuroscience Letters

Volumn 449, Issue 1, 2009, Pages 81-83

  Klotz, Luisa ^a   Schmidt, Stephan ^a   Heun, Reinhard ^a   Klockgether, Thomas ^a   Kölsch, Heike ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Multiple sclerosis; Polymorphism; PPAR

Indexed keywords

ALANINE; LEUCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; VALINE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; ADOLESCENT; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEALTH CARE PLANNING; MIDDLE AGED; ONSET AGE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ALANINE; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; YOUNG ADULT;

EID: 56449084136     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.10.066     Document Type: Article

References (22)

1. Al-Shali K.Z., House A.A., Hanley A.J., Khan H.M., Harris S.B., Zinman B., Mamakeesick M., Fenster A., Spence J.D., and Hegele R.A. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35 (2004) 2036-2040
2. Brune S., Kolsch H., Ptok U., Majores M., Schulz A., Schlosser R., Rao M.L., Maier W., and Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J. Neural Transm. 110 (2003) 1041-1050
3. Butt C., Gladman D., and Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J. Rheumatol. 33 (2006) 1631-1633
4. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., and Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20 (1998) 284-287
5. Doney A.S., Fischer B., Cecil J.E., Boylan K., McGuigan F.E., Ralston S.H., Morris A.D., and Palmer C.N. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47 (2004) 555-558
6. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
7. Frederiksen L., Brodbaek K., Fenger M., Jorgensen T., Borch-Johnsen K., Madsbad S., and Urhammer S.A. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J. Clin. Endocrinol. Metab. 87 (2002) 3989-3992
8. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 6 (2006) 44-55
9. J.L. Haines, M. Ter-Minassian, A. Bazyk, J.F. Gusella, D.J. Kim, H. Terwedow, M.A. Pericak-Vance, J.B. Rimmler, C.S. Haynes, A.D. Roses, A. Lee, B. Shaner, M. Menold, E. Seboun, R.P. Fitoussi, C. Gartioux, C. Reyes, F. Ribierre, G. Gyapay, J. Weissenbach, S.L. Hauser, D.E. Goodkin, R. Lincoln, K. Usuku, J.R. Oksenberg, A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group, Nat. Genet. 13 (1996) 469-471.
10. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 291-301
11. Herrmann S.M., Ringel J., Wang J.G., Staessen J.A., and Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51 (2002) 2653-2657
12. Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., and Heneka M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175 (2005) 4948-4955
13. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 (2004) 5790-5798
14. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., and Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39 (2007) 1108-1113
15. Masugi J., Tamori Y., Mori H., Koike T., and Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun. 268 (2000) 178-182
16. Natarajan C., Muthian G., Barak Y., Evans R.M., and Bright J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171 (2003) 5743-5750
17. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
18. Robitaille J., Brouillette C., Houde A., Lemieux S., Perusse L., Tchernof A., Gaudet D., and Vohl M.C. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 49 (2004) 482-489
19. Stumvoll M., and Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51 (2002) 2341-2347
20. Tanaka T., Itoh H., Doi K., Fukunaga Y., Hosoda K., Shintani M., Yamashita J., Chun T.H., Inoue M., Masatsugu K., Sawada N., Saito T., Inoue G., Nishimura H., Yoshimasa Y., and Nakao K. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42 (1999) 702-710
21. Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Zawadzki C., Haulon S., Kubaszek A., Koehler C., Leonhardt W., Staels B., and Laakso M. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J. Clin. Endocrinol. Metab. 89 (2004) 4238-4242
22. Yao Q., Nordfors L., Axelsson J., Heimburger O., Qureshi A.R., Barany P., Lindholm B., Lonnqvist F., Schalling M., and Stenvinkel P. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 182 (2005) 105-111